三生国健: 三生国健：2024年度环境、社会和公司治理报告

Group 1 - The core viewpoint of the news is the emphasis on the company's commitment to environmental, social, and governance (ESG) practices, highlighting its role as a long-term pioneer in the health industry, a reliable provider of antibody drugs, a stable creator of social value, and a long-term actor in green initiatives [1] Group 2 - The company conducts annual compliance training on anti-commercial bribery and anti-corruption for all employees, board members, and third-party partners to prevent corruption [2] - A risk compliance department is established to handle reports of non-compliance, ensuring that all reports are documented and investigated appropriately [2] - The company has implemented a commercial secret management policy, which includes regular assessments and self-checks to optimize and improve the protection of commercial secrets [2] Group 3 - The company has a structured process for handling non-conforming products, including documentation, review, and final approval of the handling methods by quality management [3] - A recall process is in place that includes decision-making, preparation, initiation, evaluation, and summary of the recall actions [3] Group 4 - The company has established a talent development plan that includes personalized performance evaluations and incentives to encourage employee growth and retention [5] - A long-term service award system is in place to reward employees who have served for 10 and 20 years, along with a referral bonus for recommending talented candidates [5] - The company has implemented an equity incentive mechanism that covers 12% of all employees, aimed at motivating high-performance staff [5]